As a pioneer in antibody-drug conjugates (ADCs), Seagen has led the way in novel cancer therapeutics for more than 20 years. We’re committed to discovering safe and effective solutions to challenging clinical needs. Today, our research efforts are dedicated to advancing a pipeline of innovative therapies for solid tumours and blood-related cancers.